www.wuxibiologics.com
Open in
urlscan Pro
163.171.132.119
Public Scan
Submitted URL: http://wuxibiologics.com/
Effective URL: https://www.wuxibiologics.com/
Submission: On October 10 via api from US — Scanned from DE
Effective URL: https://www.wuxibiologics.com/
Submission: On October 10 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
* Home
* About Us
* Services & Solutions
* Careers
* Investors
* News & Media
* Contact Us
* CN
* DE
* 日本語
About Us
* Company
* Leadership
* Scientific Advisory Board
* Locations & Facilities
Company
* Vision & Mission
* Culture
* History & Awards
* Business Ethics
* ESG
Locations & Facilities
* Global Network
* Virtual Tour
Services & Solutions
* Technologies
* Discovery
* Mammalian
* Microbial
* Viral Vaccines
* WuXi XDC – Bioconjugation
* Testing
Technologies
* Discovery
* Development
* Manufacturing
* Centers of Excellence
* CRISPR/Cas9 Gene Editing Services
Discovery
* Research Materials Generation
* Antibody Generation
* Lead Optimization
* Lead Characterization
* Pre-Clinical Studies
* Complex Biologics (e.g., ADCs, bispecific Abs)
Mammalian
* R&D Protein Generation
* Cell Line Development
* Upstream Development
* Downstream Development
* Analytical Development
* Drug Product Development
* GMP Manufacturing
* DNA to IND Integrated Services
Microbial
* Plasmid DNA
* Recombinant Proteins and Enzymes
* High Quality and cGMP Manufacturing
Viral Vaccines
* Viral Vectors for Vaccines
* Viral Vaccine Process Development
* Viral Vaccine Analytical Testing
* Viral Vaccine GMP Formulation and Fill
WuXi XDC – Bioconjugation
* Overview
* Conjugation R&D
* Analytical and Formulation
* GMP Conjugation Manufacturing
* GMP Formulation, Fill and Lyophilization
* Payload and Linker Manufacturing
Testing
* Biosafety Testing
* Analytical Testing
Careers
* What We Value
* Meet our people
* Join us
What We Value
* PROUD
* Life
Meet our people
* Experienced Professionals
* Employee Stories Worldwide
Join us
* Job Opportunity
* Talent Pool
Investors
* Corporate Governance
* Financial Reports
* Announcements & Circulars
* Stock Information
* Investor Events
* Investors Contact
Investor Events
* Calendar
* Investor Day
* Presentations & Webcasts
News & Media
* Press Releases
* Perspectives
* Events
* Company Newsletter Archive
* Resources
Resources
* Photos
* Videos
* Webinars
* Regulatory Newsletter Archive
* Publications
WuXi Biologics
Offering End-to-End Solutions
* About Us
About Us
* Company
* Vision & Mission
* Culture
* History & Awards
* Business Ethics
* ESG
* Leadership
* Scientific Advisory Board
* Locations & Facilities
* Global Network
* Virtual Tour
* Services & Solutions
* Technologies
* Discovery
* Development
* Manufacturing
* Centers of Excellence
* CRISPR/Cas9 Gene Editing Services
* Discovery
* Research Materials Generation
* Antibody Generation
* Lead Optimization
* Lead Characterization
* Pre-Clinical Studies
* Complex Biologics (e.g., ADCs, bispecific Abs)
* Mammalian
* R&D Protein Generation
* Cell Line Development
* Upstream Development
* Downstream Development
* Analytical Development
* Drug Product Development
* GMP Manufacturing
* DNA to IND Integrated Services
* Microbial
* Plasmid DNA
* Recombinant Proteins and Enzymes
* High Quality and cGMP Manufacturing
* Viral Vaccines
* Viral Vectors for Vaccines
* Viral Vaccine Process Development
* Viral Vaccine Analytical Testing
* Viral Vaccine GMP Formulation and Fill
* WuXi XDC – Bioconjugation
* Overview
* Conjugation R&D
* Analytical and Formulation
* GMP Conjugation Manufacturing
* GMP Formulation, Fill and Lyophilization
* Payload and Linker Manufacturing
* Testing
* Biosafety Testing
* Analytical Testing
* Careers
Careers
* What We Value
* PROUD
* Life
* Meet our people
* Experienced Professionals
* Employee Stories Worldwide
* Join us
* Job Opportunity
* Talent Pool
* Investors
Investors
* Corporate Governance
* Financial Reports
* Announcements & Circulars
* Stock Information
* Investor Events
* Calendar
* Investor Day
* Presentations & Webcasts
* Investors Contact
* News & Media
News & Media
* Press Releases
* Perspectives
* Events
* Company Newsletter Archive
* Resources
* Photos
* Videos
* Webinars
* Regulatory Newsletter Archive
* Publications
CN
DE
日本語
Contact Us
菜单
* Home
* About Us
* Company
* Vision & Mission
* Culture
* History & Awards
* Business Ethics
* ESG
* Leadership
* Scientific Advisory Board
* Locations & Facilities
* Global Network
* Virtual Tour
* Services & Solutions
* Technologies
* Discovery
* Development
* Manufacturing
* Centers of Excellence
* CRISPR/Cas9 Gene Editing Services
* Discovery
* Research Materials Generation
* Antibody Generation
* Lead Optimization
* Lead Characterization
* Pre-Clinical Studies
* Complex Biologics (e.g., ADCs, bispecific Abs)
* Mammalian
* R&D Protein Generation
* Cell Line Development
* Upstream Development
* Downstream Development
* Analytical Development
* Drug Product Development
* GMP Manufacturing
* DNA to IND Integrated Services
* Microbial
* Plasmid DNA
* Recombinant Proteins and Enzymes
* High Quality and cGMP Manufacturing
* Viral Vaccines
* Viral Vectors for Vaccines
* Viral Vaccine Process Development
* Viral Vaccine Analytical Testing
* Viral Vaccine GMP Formulation and Fill
* WuXi XDC – Bioconjugation
* Overview
* Conjugation R&D
* Analytical and Formulation
* GMP Conjugation Manufacturing
* GMP Formulation, Fill and Lyophilization
* Payload and Linker Manufacturing
* Testing
* Biosafety Testing
* Analytical Testing
* Careers
* What We Value
* PROUD
* Life
* Meet our people
* Experienced Professionals
* Employee Stories Worldwide
* Join us
* Job Opportunity
* Talent Pool
* Investors
* Corporate Governance
* Financial Reports
* Announcements & Circulars
* Stock Information
* Investor Events
* Calendar
* Investor Day
* Presentations & Webcasts
* Investors Contact
* News & Media
* Press Releases
* Perspectives
* Events
* Company Newsletter Archive
* Resources
* Photos
* Videos
* Webinars
* Regulatory Newsletter Archive
* Publications
* Contact Us
* CN
* DE
* 日本語
Contact Us LinkedIn YouTube Twitter info@wuxibiologics.com
WUXI BIOLOGICS OFFERING END-TO-END SOLUTIONS
DISCOVERY FROM TARGET TO DRUG CANDIDATE
DEVELOPMENT 12 MONTHS FROM DNA TO IND
MANUFACTURING GLOBAL DUAL SOURCING
* DISCOVERY FROM TARGET TO DRUG CANDIDATE
* DEVELOPMENT 12 MONTHS FROM DNA TO IND
* MANUFACTURING GLOBAL DUAL SOURCING
* WUXI BIOLOGICS OFFERING END-TO-END SOLUTIONS
* DISCOVERY FROM TARGET TO DRUG CANDIDATE
* DEVELOPMENT 12 MONTHS FROM DNA TO IND
* MANUFACTURING GLOBAL DUAL SOURCING
* WUXI BIOLOGICS OFFERING END-TO-END SOLUTIONS
* DISCOVERY FROM TARGET TO DRUG CANDIDATE
* DEVELOPMENT 12 MONTHS FROM DNA TO IND
* Vision & Mission
* Culture
* History & Awards
* Business Ethics
* ESG
SERVICES
& SOLUTIONS
A global Contract Research, Development and Manufacturing Organization (CRDMO)
offering end-to-end solutions that enable partners to discover, develop and
manufacture biologics.
TECHNOLOGIES
Technology platforms that span the entire drug discovery to manufacturing
spectrum.
WUXI XDC
A WuXi Biologics subsidiary, greatly simplifies bioconjugate development and
manufacturing.
DISCOVERY
One-stop target identification to lead preclinical candidate (PCC) platform.
MAMMALIAN
Unparalleled capacities and expertise for the discovery, development and cGMP
manufacture of biologics from concept to commercialization.
TESTING
Providing extensive expertise and high-quality biosafety testing under EMA, ISO
(CNAS) and CMA certified laboratories.
MICROBIAL
E.coli and yeast based expression systems, process development and cGMP
manufacturing platform
QUALITY
World-class quality systems approved by the U.S. FDA, EMA and NMPA.
VIRAL
Viral vector based vaccine and therapeutic virus development and cGMP
manufacturing platform.
LOCATIONS
Total estimated capacity for biopharmaceutical production in China, Ireland, the
U.S., Germany and Singapore to exceed 580,000 liters by 2026.
United States
Massachusetts
U.S.
189,500sq. ft.
Operational2024
Learn More
New Jersey
U.S.
66,000sq. ft.
Operational2021
Learn More
Pennsylvania
U.S.
33,000sq. ft.
OperationalOctober. 2020
Learn More
Ireland
Dundalk
Ireland
26Hectare campus
Operational2022
Learn More
WuXi Vaccines
Ireland
$240Million investment
Operational2022
Learn More
Germany
Leverkusen
Germany
13,000+sq.m. facility
Operations2020
Learn More
Wuppertal
Germany
30,000+sq.m.
Operations2021
Learn More
Singapore
Singapore
$14Million investment
Operational2026
Learn More
China
Shanghai
Waigaoqiao Free Trade Zone
200,000 sq.ft
Opened April 2018
Learn More
Shanghai
Fengxian District
1.6 millionsq. ft.
Planned2021
Learn More
Wuxi
15,296sq.m.
OpenedOctober 2012
Learn More
Suzhou
16,000sq. m.
OpenedDecember 2014
Learn More
Hangzhou
30,000sq. m.
Operations2021
Learn More
Chengdu
314,000sq. m.
Planned2023
Learn More
Shijiazhuang
82,160sq. m.
Planned2022
Learn More
Hangzhou
50,000sq. m.
Operations2021
Learn More
Suzhou
11,500sq. m.
Operations2021
Learn More
WORLD-CLASS QUALITY
We provide quality assurance, quality control and operational systems that meet
or exceed worldwide regulatory standards. Our premier world-class quality
systems have been approved by multiple global regulatory agencies for a wide
variety of biologics and vaccines.
Learn More
As of July, 2022
11
GMP Facilities Certified
9
Audits from Different Global Regulatory Agencies
25
Successful Regulatory Agency Inspections
760
Successful Client Quality Audits
CULTURE
Integrity, Dedication, Working Together & Sharing Success
* Put Customers First
Exceed customers’ expectations, maximize the value for our customers, and win
customers’ loyalty with a 100% customer retention rate.
* Demonstrate Integrity
Take the initiative to promote a positive work environment where doing the
right thing is the standard. Be positive and enthusiastic, approach
challenges with energy and optimism.
* Strive for Excellence
Pursue focus and expertise, and optimize processes in order to deliver
excellent results. Relentlessly drive learning, accumulation, improvement and
innovation.
* Execute for Results
Drive effective execution of each project and objective, focusing on
solutions and results.
* Pursue Collaboration and Teamwork
Engage in collaboration and mutual development with an open and win-win
mindset by sharing resources and leveraging the complementary advantages of
each.
* Embrace Change and Drive Innovation
Demonstrate flexibility and ability to embrace change. Adapt quickly to
transformational and innovative conditions with a strong commitment to
breakthroughs and development.
ENVIRONMENTAL SOCIAL GOVERNANCE (ESG)
We are dedicated to implementing sustainable and eco-friendly business practices
by building a comprehensive and integrated Environmental, Health and Safety
(EHS) management system, sourcing ethically, reducing our environmental
footprint, advocating reduced energy consumption, minimizing effluent, and
acting responsibly to reduce operational impact on the environment.
Learn More
* CAREERS
WuXi Biologics offers exciting job opportunities and careers around the
globe. Come be a part of our PROUD (Passion, Reward, Ownership, Unity &
Determination) culture and embrace the challenges and new opportunities as we
work together to enable our clients and benefit patients worldwide.
Learn More
SUBSCRIBE TO OUR NEWSLETTER
Stay up-to-date on our latest news, financial results and capabilities at our
sites around the globe!
Subscribe Now
LATEST NEWS
Learn More
* News
Sep. 28, 2022
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing
Facility in Worcester, Massachusetts
* News
Sep. 20, 2022
WuXi Biologics’ Drug Substance and Drug Product Facilities Again Approved by
U.S. FDA and EMA
* News
Aug. 31, 2022
WuXi Biologics Announces GMP Release of Its First North American
Biomanufacturing Facility in Cranbury, New Jersey
* News
Sep. 28, 2022
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing
Facility in Worcester, Massachusetts
* News
Sep. 20, 2022
WuXi Biologics’ Drug Substance and Drug Product Facilities Again Approved by
U.S. FDA and EMA
* News
Aug. 31, 2022
WuXi Biologics Announces GMP Release of Its First North American
Biomanufacturing Facility in Cranbury, New Jersey
* News
Sep. 28, 2022
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing
Facility in Worcester, Massachusetts
* News
Sep. 20, 2022
WuXi Biologics’ Drug Substance and Drug Product Facilities Again Approved by
U.S. FDA and EMA
* News
Aug. 31, 2022
WuXi Biologics Announces GMP Release of Its First North American
Biomanufacturing Facility in Cranbury, New Jersey
* Connect with our Experts Let's discuss your project needs
Contact Us Now
* Contact
General Inquiries
Newsletter Sign-Up
Join Us
Compliance Reporting
* Services & Solutions
Technologies
Discovery
Mammalian
Microbial
WuXi XDC / Bioconjugates
Viral
Testing
* Company
About Us
ESG
Careers
Investors
News & Media
Terms of Use | Privacy Policy | Cookie Policy
Copyright © 2022 WuXi Biologics. All Rights Reserved. 苏ICP备16033595号 苏公网安备
32021102001100号
We use cookies that are necessary for our website to function properly. We also
use cookies to retain user preferences, for analysing our website traffic and
for statistical and web-traffic marketing purposes. By clicking “accept all”,
you provide your specific and active consent for the use
of last-mentioned categories of cookies. To see a list of the cookies and their
purpose, click here. Please see section 6 in our Privacy Policy for more
information on (i) how we use cookies and (ii) your rights and actions in
relation to data protection.
Accept All
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not
apply. Please keep it in mind the protection of your privacy. Are you willing to
proceed?
Yes, continue to proceed
No, stay on this Website
WE CARE ABOUT YOUR PRIVACY
Publisher
Vendors
Manage Settings
Vendors
PUBLISHER SETTINGS
PURPOSES
WE AND OUR PARTNERS CAN:
Store and/or access information on a device
Select basic ads
Create a personalised ads profile
Select personalised ads
Create a personalised content profile
Select personalised content
Measure ad performance
Measure content performance
Apply market research to generate audience insights
Develop and improve products
VENDOR SETTINGS
PURPOSES
VENDORS CAN:
Store and/or access information on a device
Select basic ads
Create a personalised ads profile
Select personalised ads
Create a personalised content profile
Select personalised content
Measure ad performance
Measure content performance
Apply market research to generate audience insights
Develop and improve products
SPECIAL PURPOSES
VENDORS CAN:
* Ensure security, prevent fraud, and debug
* Technically deliver ads or content
FEATURES
VENDORS CAN:
* Match and combine offline data sources
* Link different devices
* Receive and use automatically-sent device characteristics for identification
SPECIAL FEATURES
VENDORS CAN:
Use precise geolocation data
Actively scan device characteristics for identification
Some partners do not ask for your consent to process your data, instead, they
rely on their legitimate business interest. Personal data processed includes but
is not limited to cookies, IP addresses, and URLs visited. View our list of
partners to see the purposes they believe they have a legitimate interest for
and object to legitimate interests on a per vendor basis. Manage your settings
and object to purposes as a legitimate interest in general.
You can change your settings at any time, including by withdrawing your consent,
by clicking on the cog icon in the bottom right hand corner.
Manage Settings
Vendors
Accept All
Reject All
Save & Exit